Multifunctional iRGD–Pt–Iodine–W ₁₈ O ₄₉ Nanoparticles with Low Cisplatin-Induced Nephrotoxicity for Gastric Cancer Theranostics

Multifunctional nanoparticles are able to achieve multiple purposes such as imaging and therapy simultaneously through modification with multiple functional units and have significant advantages in cancer theranostics. Among the multifunctional nanoparticles, W18O49 NP-mediated multimodality theranostics are restricted by their undesirable tumor selectivity. In this study, we develop multifunctional iRGD–Pt–Iodine–W18O49 NPs (i–P–I–W) based on W18O49 NPs, which integrates computed tomography (CT) imaging, PA imaging, chemotherapy, photodynamic therapy (PDT), and photothermal therapy (PTT) properties in a single targeting manner. Due to the presence of an iRGD peptide, tungsten, and iodine, these iRGD–Pt–Iodine–W18O49 NPs exhibit targeting contrasting ability for CT and PA imaging. Combined with cisplatin, the iRGD–Pt–Iodine–W18O49 NPs display remarkable targeting synergistic antitumor effects in vitro and in vivo. Meanwhile, iRGD–Pt–Iodine–W18O49 NPs are capable of alleviating the cisplatin-induced nephrotoxicity at the administration dosage. Therefore, iRGD–Pt–Iodine–W18O49 NPs are expected to be used in targeting CT/PA dual-imaging guided side effects relieving chemotherapy/PDT/PTT multimodality precise therapy of gastric cancer.